HCW Biologics (NASDAQ:HCWB) Stock Price Down 1.6%

HCW Biologics Inc. (NASDAQ:HCWB) was down 1.6% on Tuesday . The company traded as low as $1.44 and last traded at $1.60. Approximately 8,757 shares changed hands during mid-day trading, a decline of 43% from the average daily volume of 15,365 shares. The stock had previously closed at $1.63.

HCW Biologics Stock Performance

The business has a 50 day moving average price of $1.54 and a two-hundred day moving average price of $1.38. The company has a market cap of $60.65 million, a P/E ratio of -2.29 and a beta of 0.97. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.73 and a current ratio of 0.73.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in HCW Biologics stock. Avantax Planning Partners Inc. bought a new position in shares of HCW Biologics Inc. (NASDAQ:HCWB) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 179,541 shares of the company’s stock, valued at approximately $220,000. Avantax Planning Partners Inc. owned 0.50% of HCW Biologics as of its most recent filing with the Securities and Exchange Commission. 2.96% of the stock is currently owned by institutional investors and hedge funds.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.